Not logged in The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial Elisa Agostinetto, MD; Gabriella Gentile, MD; Faye Samy, BSc; Serena Di Cosimo, MD PhD; Philippe Aftimos, MD; Noam Pondé, MD; Daniel Eiger, MD; Matteo Lambertini, MD PhD; David Cameron, MSc MD; Astrid Kiermaier, PhD; Andrew Bailey, MSc; Giuseppe Viale, MD; Sherene Loi, MD PhD; Martine Piccart, MD PhD; Evandro de Azambuja, MD PhD Share Save
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer Kuemmel, Sherko; Harper-Wynne, Catherine; Park, Yeon Hee; Franke, Fabio; de Laurentiis, Michelino; Schumacher-Wulf, Eva; Eiger, Daniel; Heeson, Sarah; Cardona, Andres; Ozyilkan, Ozgur; Morales-Vasquez, Flavia; Metcalfe, Ciara; Hafner, Marc; Restuccia, Eleonora; O'Shaughnessy, Joyce Share Save
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial de Azambuja, Evandro; Agostinetto, Elisa; Samy, Faye; Di Cosimo, Serena; Aftimos, Philippe; Ponde, Noam; Eiger, Daniel; Lambertini, Matteo; Cameron, David; Kiermaier, Astrid; Bailey, Andrew; Viale, Giuseppe; Loi, Sherene; Piccart, Martine Share Save
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study Martins-Branco, Diogo; Kassapian, Marie; Debien, Veronique; Caparica, Rafael; Eiger, Daniel; Dafni, Urania; Andriakopoulou, Charitini; El-Abed, Sarra; Ellard, Susan L.; Izquierdo, Miguel; Vicente, Malou; Chumsri, Saranya; Piccart-Gebhart, Martine; Moreno-Aspitia, Alvaro; Knop, Ann Soegaard; Lombard, Janine; de Azambuja, Evandro Share Save
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial Buisseret, Laurence; Loirat, Delphine; Aftimos, Philippe; Maurer, Christian; Punie, Kevin; Debien, Veronique; Kristanto, Paulus; Eiger, Daniel; Goncalves, Anthony; Ghiringhelli, Francois; Taylor, Donatienne; Clatot, Florent; Van den Mooter, Tom; Ferrero, Jean-Marc; Bonnefoi, Herve; Canon, Jean-Luc; Duhoux, Francois P.; Mansi, Laura; Poncin, Renaud; Barthelemy, Philippe; Isambert, Nicolas; Denis, Zoe; Catteau, Xavier; Salgado, Roberto; Agostinetto, Elisa; de Azambuja, Evandro; Rothe, Francoise; Craciun, Ligia; Venet, David; Romano, Emanuela; Stagg, John; Paesmans, Marianne; Larsimont, Denis; Sotiriou, Christos; Ignatiadis, Michail; Piccart-Gebhart, Martine Share Save
heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+advanced breast cancer Kuemmel, Sherko; Harper-Wynne, Catherine; Park, Yeon H.; Franke, Fabio; De laurentiis, Michelino; Schumacher-Wulf, Eva; Eiger, Daniel; Heeson, Sarah; Shivhare, Mahesh; Restuccia, Eleonora; O'Shaughnessy, Joyce Share Save
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial de Azambuja, E.; Agostinetto, E.; Procter, M.; Eiger, D.; Ponde, N.; Guillaume, S.; Parlier, D.; Lambertini, M.; Desmet, A.; Caballero, C.; Aguila, C.; Jerusalem, G.; Walshe, J. M.; Frank, E.; Bines, J.; Loibl, S.; Piccart-Gebhart, M.; Ewer, M. S.; Dent, S.; Plummer, C.; Suter, T. Share Save
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study Nader-Marta, Guilherme; Debien, Veronique; Eiger, Daniel; Tsourti, Zoi; Caparica, Rafael; Kassapian, Marie; Napoleone, Sylvia; Hultsch, Susanne; Korde, Larissa; Wang, Yingbo; Chumsri, Saranya; Pritchard, Kathleen, I; Untch, Michael; Bellet-Ezquerra, Meritxell; Rosa, Daniela Dornelles; Moreno-Aspitia, Alvaro; Piccart, Martine; Dafni, Urania; de Azambuja, Evandro Share Save
The impact of erythropoietin administration concomitantly with adjuvant anti-HER2 treatment on the patients' outcome: Sub-analysis of the ALTTO study Martins-Branco, Diogo; Kassapian, Marie; Debien, Veronique; Caparica, Rafael; Eiger, Daniel; Dafni, Urania; Andriakopoulou, Charitini; El-Abed, Sarra; Izquierdo, Miguel; Vicente, Malou; Chumsri, Saranya; Piccart-Gebhart, Martine; Moreno-Aspitia, Alvaro; Knop, Ann Soegaard; Lombard, Janine; de Azambuja, Evandro Share Save
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial De Caluwe, Alex; Buisseret, Laurence; Poortmans, Philip; Van Gestel, Dirk; Salgado, Roberto; Sotiriou, Christos; Larsimont, Denis; Paesmans, Marianne; Craciun, Ligia; Stylianos, Drisis; Vandekerckhove, Christophe; Reyal, Fabien; Isabelle, Veys; Eiger, Daniel; Piccart, Martine; Romano, Emanuela; Ignatiadis, Michail Share Save
VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab plus pertuzumab plus trastuzumab plus chemotherapy (neoadj A plus PH plus CT) in high-risk, HER2-positive early breast cancer (EBC) Huober, J.; Barrios, C. H.; Niikura, N.; Jarzab, M.; Chang, Y-C.; Huggins-Puhalla, S. L.; Graupner, V.; Eiger, D.; Henschel, V.; Gochitashvili, N.; Lambertini, C.; Restuccia, E.; Zhang, H. Share Save
Share Save
Original Research Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials Agostinetto, Elisa; Eiger, Daniel; Lambertini, Matteo; Ceppi, Marcello; Bruzzone, Marco; Ponde, Noam; Plummer, Chris; Awada, Ahmad H.; Santoro, Armando; Piccart-Gebhart, Martine; de Azambuja, Evandro Share Save
Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial Dang, C.; Ewer, M. S.; Delaloge, S.; Ferrero, J-M.; Colomer, R.; de la Cruz Merino, L.; Dadswell, K.; Verrill, M.; Eiger, D.; Sarkar, S.; de Haas, S.; Restuccia, E.; Swain, S. M. Share Save
Impact of HIV infection on baseline characteristics and survival of women with breast cancer Brandao, Mariana; Bruzzone, Marco; Franzoi, Maria-Alice; De Angelis, Claudia; Eiger, Daniel; Caparica, Rafael; Piccart-Gebhart, Martine; Buisseret, Laurence; Ceppi, Marcello; Dauby, Nicolas; Carrilho, Carla; Lunet, Nuno; de Azambuja, Evandro; Lambertini, Matteo Share Save
Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial De Caluwe, A.; Buisseret, L.; Poortmans, P.; Sotiriou, C.; Larsimont, D.; Van Gestel, D.; Laragione, A.; Desmet, A.; Van den Begin, R.; Philippson, C.; Eiger, D.; Piccart, M.; Romano, E.; Ignatiadis, M. Share Save
The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: A systematic review and meta-analysis Eiger, D.; Agostinetto, E.; Caparica, R.; Franzoi, M. A.; Brandao, M.; Buisseret, L.; de Caluwe, A.; Gimenes, D.; Simon, S. D.; Ponde, N. F.; de Azambuja, E. Share Save
Cardiotoxicity of immune checkpoint inhibitors: A meta-analysis of randomized clinical trials Agostinetto, E.; Eiger, D.; Lambertini, M.; Ceppi, M.; Bruzzone, M.; Ponde, N. F.; Plummer, C.; Awada, A. H.; Piccart, M.; de Azambuja, E. Share Save
Long-term outcomes of patients with node-negative, ≤3cm, HER2+breast cancer (BC) enrolled in ALTTO Eiger, D.; Tsourti, Z.; Caparica, R.; Kassapian, M.; Napoleone, S.; Hultsch, S.; Korde, L.; Wang, Y.; Chumsri, S.; Pritchard, K.; Untch, M.; Bellet Ezquerra, M.; Rosa, D. D.; Moreno-Aspitia, A.; Piccart, M.; Dafni, U.; de Azambuja, E. Share Save
First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC) Eiger, D.; Maurer, C.; Brandao, M.; Aftimos, P. G.; Punie, K.; Taylor, D.; Van den Mooter, T.; Poncin, R.; Canon, J-L.; Duhoux, F.; Casert, V.; Clatot, F.; Velghe, C.; Craciun, L.; Paesmans, M.; de Azambuja, E.; Ignatiadis, M.; Larsimont, D.; Piccart, M.; Buisseret, L. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
BMC CANCER.png)
OAAI
.png){kind=icon}
Share.png){kind=icon}
Save